Head to Head Analysis: Vaccinex (NASDAQ:VCNX) versus Silverback Therapeutics (NASDAQ:SBTX)

Institutional & Insider Ownership

74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Comparatively, 51.5% of Vaccinex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Silverback Therapeutics and Vaccinex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Vaccinex	N/A	N/A	-383.58%

Earnings & Valuation

This table compares Silverback Therapeutics and Vaccinex”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48 million	($2.42)	-4.33
Vaccinex	$388,000.00	6.03	-$20.25 million	($48.27)	-0.02

Vaccinex has higher revenue and earnings than Silverback Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Silverback Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Vaccinex has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.

Summary

Vaccinex beats Silverback Therapeutics on 6 of the 9 factors compared between the two stocks.

About Silverback Therapeutics

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

About Vaccinex

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.